PS
ARCT icon

Principal Securities’s Arcturus Therapeutics ARCT Stock Holding History

Principal Securities’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36
Closed -$663 – 1462
2025
Q3 		$663 Sell
36
-19
-35% -$305 ﹤0.01% 3485
2025
Q2 		$716 Hold
55
– – ﹤0.01% 3409
2025
Q1 		$933 Hold
55
– – ﹤0.01% 3229
2024
Q4 		$933 Hold
55
– – ﹤0.01% 3222
2024
Q3 		$1.28K Hold
55
– – ﹤0.01% 3081
2024
Q2 		$1.34K Sell
55
-10
-15% -$303 ﹤0.01% 3008
2024
Q1 		$2.19K Sell
65
-11
-14% -$390 ﹤0.01% 2853
2023
Q4 		$2.4K Buy
+76
New +$1.81K ﹤0.01% 2765

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Principal Securities's ARCT Position: Q4 2025 in Review

Principal Securities sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 36 shares — an estimated $663 sold.

Principal Securities first reported a position in ARCT in Q4 2023 and held it in 8 quarters. The position peaked at $2.4K in Q4 2023. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Principal Securities reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 36 Arcturus Therapeutics shares in Q4 2025, an estimated $663.
  • Principal Securities first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Arcturus Therapeutics position peaked at $2.4K in Q4 2023.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.